The Week in Review: October 27 – November 4, 2017

Friday, November 4, 2017 News Recap: Access to Treatment Hepatitis C could be eliminated in Canada, but drug prices, screening barriers stand in the way – Most of the 70 million patients infected with hepatitis C worldwide could be cured for $50 US each Many countries — including Canada — have committed to a global goal of eliminating hepatitis C by 2030. But new data released at the summit in Brazil shows that only nine countries are on track to me...

Fatty Liver Common After Direct-Acting Antivirals for Hep C

The study showed that even after achieving a cure for hepatitis C, approximately 50% of those patients demonstrated evidence of NAFLD. WASHINGTON, DC — Evidence of steatosis is found in almost half the patients with hepatitis C who achieved a sustained virologic response after treatment with direct-acting antivirals, results from a prospective study show. "Fatty liver is very common now that hepatitis C is being treated effectively," said Mazen Nouredd

The Week in Review: October 13 – October 20, 2017

Friday, October 20, 2017 News Recap: Disease Management: Women: Hepatitis C in pregnancy: screening, treatment, and management. Hepatitis C (HCV) during pregnancy is associated with serious, adverse outcomes. Infants born to women with HCV are more likely to experience fetal growth restriction and low birth weight. For women, chronic HCV is associated with progressive liver damage and, during pregnancy, can be transmitted from the mother to the fe...

Cannabis May Be Protective Against Steatosis in Persons Coinfected with HIV-HCV

MARSEILLE, FRANCE — Cannabis may be protective against liver disease in subjects infected with both the hepatitis C virus (HCV) and the human immunodeficiency virus (HIV), according to data published online ahead of print in the Journal of Viral Hepatitis. French investigators assessed the relationship between cannabis use and the prevalence of steatosis (fatty liver disease) in a cohort of 838 HIV-HCV co-infected subjects. They reported, “Daily cannab

The Week in Review: August 11 – August 18, 2017

Friday, August 18, 2017 Canada Great news in Canada. Two new drug regimens have been approved:  Vosevi from Gilead is a pangenotypic for retreatment of those who have failed previous DAA therapy Gilead Receives Approval in Canada for VOSEVI™ (Sofosbuvir/Velpatasvir/Voxilaprevir) for Re-treatment of Certain Patients with Chronic Hepatitis C Virus (HCV) Infection. And MAVIRET from AbbVie is the first and only 8-week, pan-genotypic treatment for hepatit...

Steatosis: An Independent Risk Factor for Fibrosis in Chronic HCV

Steatosis is an independent risk factor for fibrosis in African-Americans with chronic HCV infection. A study recently published in Digestive Disease Science found that hypertension, older age, obesity, and HIV are risk factors and that steatosis is an independent risk factor for liver fibrosis in African-Americans with chronic hepatitis C. "Our retrospective study showed that there are risk factors, such as HIV coinfection for progression of liver fib